Anaplastic large cell lymphoma with primary involement of skeletal muscle: A rare case report and review of the literature

Pediatric Hematology and Oncology

Volumn 26, Issue 3, 2009, Pages 142-149

  Wu, Liang ^a   Wang, Ying ^a   Fu, Sheng Ling ^a   Huang, Liu ^a   Tongji, Fang Chen ^a   Qi, Jun Ying ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Anaplastic large cell lymphoma; Immunohistochemistry; Skeletal muscular neoplasms

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD3 ANTIGEN; CD30 ANTIGEN; CD45RO ANTIGEN; CD68 ANTIGEN;

ADOLESCENT; ARTICLE; BACK MUSCLE; CANCER INVASION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; MUSCLE BIOPSY; MUSCLE CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; RARE DISEASE; ECHOGRAPHY; IMMUNOPHENOTYPING; MUSCLE TUMOR; PATHOLOGY; REVIEW; SKELETAL MUSCLE;

ADOLESCENT; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MAGNETIC RESONANCE IMAGING; MALE; MUSCLE NEOPLASMS; MUSCLE, SKELETAL;

EID: 67651151235     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010902771531     Document Type: Article

References (33)

1. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848-858.
2. Medeiros LJ, Elenitoba-Johnson KS. Anaplastic large cell lymphoma. Am J Clin Pathol. 2007;127:707-722.
3. Glass AG, Karnell LH, Menck HR. The National Cancer Data Base report on non-Hodgkin's lymphoma. Cancer. 1997;80:2311-2320.
4. Keung YK, Liang R. Report of a case of primary skeletal muscle lymphoma and review of the literature. Acta Haematol. 1996;96:184-186.
5. Delsol GRE, Stein H,et al. Anaplastic large cell lymphoma. In: Jaffe ES, Harris NL, Stein H, etal., eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001:230-235.
6. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681-3695.
7. FaliniB. Anaplastic large cell lymphoma: Pathological, molecular and clinical features.Br J Haematol. 2001;114:741-760.
8. Jacobsen E. Anaplastic large-cell lymphoma, T-/null-cell type. Oncologist. 2006;11:831-840.
9. Amin HM, Lai R. Pathobiology of ALK+anaplastic large-cell lymphoma. Blood. 2007;110:2259-2267.
10. Rosso R, Paulli M, Magrini U, et al. Anaplastic large cell lymphoma, CD30/Ki-1 positive, expressing the CD15/Leu-M1 antigen: Immunohistochemical and morphological relationships to Hodgkin's disease. Virchows Arch A Pathol Anat Histopathol. 1990;416:229-235.
11. Tamaru J, Tokuhira M, Nittsu N, et al. Hodgkin-like anaplastic large cell lymphoma (previously designated in the REAL classification) has same immunophenotypic features to classical Hodgkin lymphoma. Leuk Lymphoma. 2007;48:1127-1138.
12. Juco J, Holden JT, Mann KP, Kelley LG, Li S. Immunophenotypic analysis of anaplastic large cell lymphoma by flow cytometry. Am J Clin Pathol. 2003;119:205-212.
13. Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol. 1999;90:157-164.
14. Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol. 2003;40:175-184.
15. Foss HD, Anagnostopoulos I, Araujo I, et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood. 1996;88:4005-4011.
16. ten Berge RL, Snijdewint FG, von Mensdorff-Pouilly S, et al. MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form. J Clin Pathol. 2001;54:933-939.
17. Suzukawa K, Kojima H, Mori N, et al. Anaplastic large-cell lymphoma of null-cell type with multiple bone involvement. Ann Hematol. 1998;77:287-290.
18. Downing JR, Shurtleff SA, Zielenska M, et al. Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase- polymerase chain reaction. Blood. 1995;85:3416-3422.
19. Drexler HG, Gignac SM, von Wasielewski R, Werner M, Dirks WG. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia. 2000;14:1533-1559.
20. Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001;20(40):5623-37.
21. Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK +anaplastic large-cell lymphoma. Blood. 2006;108:2796-2803.
22. Lai R, Rassidakis GZ, Medeiros LJ, et al. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Am J Pathol. 2004;164:2251-2258.
23. Turner SD, Yeung D, Hadfield K, Cook SJ, Alexander DR. The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms. Cell Signal. 2007;19:740-747.
24. Amin HM, Medeiros LJ, Ma Y, et al. Inhibition of JAK3 induces apoptosis and decreases anaplasti lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene. 2003;22:5399-5407.
25. Vega F, Medeiros LJ, Leventaki V, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 2006;66:6589-6597.
26. Voena C, Conte C, Ambrogio C, et al. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res. 2007;67:4278-4286.
27. Zamo A, Chiarle R, Piva R, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene. 2002;21:1038-1047.
28. Leventaki V, Drakos E, Medeiros LJ, et al. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma. Blood. 2007;110:1621-1630.
29. Szomor A, Zenou P, Roda D, et al. Genotypic analysis in primary systemic anaplastic large cell lymphoma. Pathol Oncol Res. 2003;9:104-106.
30. Kadin ME, Carpenter C. Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hematol. 2003;40:244-256.
31. Liao WP, Dai MS, Hsu LF, Yao NS. Anaplastic large-cell lymphoma primarily infiltrating femoral muscles. Ann Hematol. 2005;84:764-766.
32. Ishii E, Honda K, Nakagawa A, Urago K, Oshima K. Primary CD30/Ki-1 positive anaplastic large cell lymphoma of skeletal muscle with der(17)t(1;17)(q11;p11). Cancer Genet Cytogenet. 2000;122:116-120.
33. Chim CS, Choy C, Liang R. Primary anaplastic large cell lymphoma of skeletal muscle presenting with compartment syndrome. Leuk Lymphoma. 1999;33:601-605.